MedPAC's Chair Defended Its Overpayment Analysis Directly to Insurers

Dr. Amol Navathe, chair of the Medicare Payment Advisory Commission (MedPAC), appeared at an industry event hosted by a group representing Medicare Advantage insurers and defended the commission's widely cited analysis of Medicare Advantage payment levels, according to Healthcare Dive, which reported the appearance on September 23, 2026. MedPAC is an independent panel that advises Congress on Medicare payment policy. It does not set payment rates itself, but its annual reports carry significant weight with lawmakers and the Centers for Medicare & Medicaid Services (CMS).

Medicare Advantage (MA) is the private-plan alternative to traditional, government-run Medicare. Insurers are paid a set amount per enrollee by CMS, adjusted for each person's expected health risk. For several years, MedPAC has published estimates suggesting MA plans are paid more per enrollee, on average, than traditional Medicare would spend for comparable beneficiaries. According to Healthcare Dive's reporting, Navathe's appearance came amid growing public debate over how best to measure and compare spending between the two programs, and his talk to an insurer-aligned audience was framed as a direct response to that pushback.

The Healthcare Dive report describes Navathe stepping into what the outlet calls "the lion's den," a signal that his MedPAC-affiliated estimate faces active criticism from the industry it affects. The specific figures and methodological details of that pushback were not included in the material reviewed for this analysis, so readers should consult the original Healthcare Dive article for the full account of what was said at the event.

Why the MA Payment Debate Keeps Resurfacing Every Year

This is not a new argument. Medicare Advantage insurers use a risk-adjustment system that pays more for enrollees coded with more or more severe diagnoses, a design meant to compensate plans fairly for sicker patients. Critics, including past MedPAC reports, have argued that MA plans have financial incentive to document diagnoses more thoroughly than traditional Medicare providers do, which can inflate risk scores and, by extension, payments, without necessarily reflecting real differences in patient health. Insurers and their trade groups counter that more complete diagnosis coding reflects better documentation and earlier detection of chronic conditions, not manipulation of the payment system.

That disagreement is the backdrop for Navathe's appearance. Because MedPAC's estimate is, as Healthcare Dive notes, "the most-cited" figure in this debate, it functions almost like a reference point for congressional staff, journalists, and policy researchers, even though it is one analytical approach among several. Insurers have pushed back on the methodology in public comments to CMS and in industry forums for years; what stands out about this event is that MedPAC's own chair chose to defend the estimate in person to an insurer-aligned audience rather than only in written commission reports.

For readers who are not policy wonks, the practical significance is this: when lawmakers debate whether to cut MA payments, restrict certain marketing practices, or tighten risk-adjustment rules, MedPAC's estimates are often part of the evidence cited to justify those changes. A sustained challenge to the estimate's credibility, or a successful defense of it, can shape how aggressively Congress or CMS moves on future MA payment policy.

Key Takeaway

This dispute is a payment-policy debate happening in Washington, not evidence that any specific Medicare Advantage plan has done anything improper. Beneficiaries do not need to take action based on this story alone, but it is worth watching because sustained pressure on MA payment levels can eventually influence future plan benefits, premiums, or provider networks.

What This Means for Your 2026 Medicare Advantage Decisions

Nothing about this specific news item changes what any current MA plan covers or costs. MedPAC's report is an advisory analysis to Congress; it does not itself alter payments, premiums, or benefits, and Healthcare Dive's report does not indicate any policy change resulted from the event. Still, the timing matters for Medicare Plan Path readers because Medicare's Annual Enrollment Period runs from October 15 to December 7, 2026, giving beneficiaries the annual window to compare, switch, or leave Medicare Advantage plans for the coming year.

A few practical steps make sense regardless of how the MedPAC debate resolves. First, review your plan's Annual Notice of Change, which every MA and Part D plan is required to send each fall, to see whether premiums, drug tiers, or provider networks are shifting for 2027. Second, if you rely on chronic condition management, check whether your plan's coding and care-management practices, such as annual wellness visits, are things your doctor's office actually schedules; thorough documentation can affect your risk score and, in turn, the resources your plan allocates to your care. Third, use Medicare's official Plan Finder tool or work with a licensed, independent Medicare agent to compare Medicare Advantage against traditional Medicare paired with a Medigap and Part D plan, since payment-policy debates like this one are one more reason cost and coverage details are worth revisiting annually rather than assuming last year's plan is still the best fit.

Finally, keep an eye on future MedPAC reports and CMS rulemaking. If Congress or CMS eventually acts on concerns about MA payment levels, whether by tightening risk-adjustment rules or adjusting benchmark rates, the changes tend to show up gradually in plan benefit designs rather than as sudden mid-year cuts. Medicare Plan Path will continue tracking how this policy debate develops and what, if anything, it means for the plans available in your area.